Appili Therapeutics Inc Class A (TSE:APLI) has released an update.
Appili Therapeutics has aligned with the FDA on the development requirements for their ATI-1801 topical antiparasitic product, simplifying its path to a New Drug Application. ATI-1801 has shown promising results in treating cutaneous leishmaniasis, potentially offering a safe outpatient therapy. Meanwhile, Appili encourages shareholders to participate in the upcoming vote regarding the acquisition by Aditxt, which promises immediate value for investors.
For further insights into TSE:APLI stock, check out TipRanks’ Stock Analysis page.
